NVCT ▲ +0.1% - Nuvectis Pharma, Inc. $NVCT - Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas 26-OCT-2026 08:30 AM ET